Lengyel A M, Mussio W, Imamura P, Vieira J G, Lancranjan I
Escola Paulista de Medicina, São Paulo, Brazil.
Fertil Steril. 1993 May;59(5):980-7. doi: 10.1016/s0015-0282(16)55914-7.
To evaluate the efficacy and tolerability of Parlodel LAR (Sandoz, Basel, Switzerland), a long-acting injectable bromocriptine, in PRL-secreting macroadenomas.
Eleven patients with macroprolactinomas were studied in an academic environment in an open and prospective protocol. Ten patients were followed for 6 months and 8 for 1 year. Fifty to 200 mg IM of Parlodel LAR were administered every 28 days.
At the end of the 1st month, 64% of the patients had PRL suppression of > 75% of baseline values. After 1 year, 88% of the cases had PRL suppression of > 90%. Persistent PRL normalization was seen in three cases. Tumor shrinkage was seen in 64% of the patients on day 5, in 73% on day 28, and in 90% after 6 months of treatment. Early visual field improvement was seen in 83% of the cases. All patients had improvement of clinical symptoms.
Parlodel LAR is well tolerated and very effective in the long-term treatment of patients with PRL-secreting macroadenomas.
评估长效注射用溴隐亭（瑞士巴塞尔山德士公司生产的Parlodel LAR）治疗泌乳素分泌型大腺瘤的疗效和耐受性。
在学术环境中，采用开放的前瞻性方案对11例大泌乳素瘤患者进行研究。10例患者随访6个月，8例随访1年。每28天肌肉注射50至200毫克Parlodel LAR。
第1个月末，64%的患者泌乳素水平抑制超过基线值的75%。1年后，88%的病例泌乳素水平抑制超过90%。3例患者泌乳素持续恢复正常。5天时64%的患者肿瘤缩小，28天时73%的患者肿瘤缩小，治疗6个月后90%的患者肿瘤缩小。83%的病例早期视野得到改善。所有患者临床症状均有改善。
Parlodel LAR耐受性良好，对泌乳素分泌型大腺瘤患者的长期治疗非常有效。
Zotero 插件